Objective:To evaluate the clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver.Methods:Randomized controlled studies were searched in Chinese and English databases from March 30,2020...Objective:To evaluate the clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver.Methods:Randomized controlled studies were searched in Chinese and English databases from March 30,2020.The quality was evaluated after literature screening and statistical analysis by RevMan5.3 software.Results:Nine studies were included,involving 780 patients.Meta analysis showed that berberine alone or in combination could reduce total cholesterol(MD=-0.50,95%CI),low density lipoprotein(MD=-0.34,95%CI)and glutamyltransferase(MD=-20.79,95CI%).Subgroup analysis showed that berberine combined with berberine could reduce glycosylated hemoglobin level[MD=-0.68,95%CI(-0.98 maxim 0.38)],while in patients with diabetes treated with berberine,alanine aminotransferase(MD=-9.38,95CI%)and aspartate oxaloacetic transaminase(MD=-9.03,95CI%)decreased significantly.The above differences were statistically significant(P<0.01).In addition,berberine has a tendency to decrease triglyceride,fasting blood glucose,body mass index and improve insulin resistance.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Berberine can regulate glucose and lipid metabolism in patients with non-alcoholic fatty liver and has a tendency to improve liver function and insulin resistance.展开更多
基金National key R&D Program Precision Medical Research key Project(No.2017YFC0910002)Beijing Science and Technology Commission G20 Engineering Innovation Research Ten Diseases and Ten drugs Research and Development Project(No.Z1711000017008)
文摘Objective:To evaluate the clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver.Methods:Randomized controlled studies were searched in Chinese and English databases from March 30,2020.The quality was evaluated after literature screening and statistical analysis by RevMan5.3 software.Results:Nine studies were included,involving 780 patients.Meta analysis showed that berberine alone or in combination could reduce total cholesterol(MD=-0.50,95%CI),low density lipoprotein(MD=-0.34,95%CI)and glutamyltransferase(MD=-20.79,95CI%).Subgroup analysis showed that berberine combined with berberine could reduce glycosylated hemoglobin level[MD=-0.68,95%CI(-0.98 maxim 0.38)],while in patients with diabetes treated with berberine,alanine aminotransferase(MD=-9.38,95CI%)and aspartate oxaloacetic transaminase(MD=-9.03,95CI%)decreased significantly.The above differences were statistically significant(P<0.01).In addition,berberine has a tendency to decrease triglyceride,fasting blood glucose,body mass index and improve insulin resistance.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Berberine can regulate glucose and lipid metabolism in patients with non-alcoholic fatty liver and has a tendency to improve liver function and insulin resistance.
